cyclophosphamide + bortezomib + pegylated liposomal doxorubicin + dexamethasone

CVDD is a four-drug combination chemotherapy regimen evaluated by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of newly diagnosed multiple myeloma. The regimen consists of cyclophosphamide (an alkylating agent), bortezomib (a proteasome inhibitor), pegylated liposomal doxorubicin (an anthracycline), and dexamethasone (a corticosteroid). It was developed to improve upon the efficacy of the VDD triplet (bortezomib, pegylated liposomal doxorubicin, and dexamethasone) in the frontline setting. In a Phase I/II clinical trial, the CVDD regimen demonstrated significant clinical activity, achieving an overall response rate of 91% in standard-risk patients and 100% in high-risk patients, with a median progression-free survival of 31.3 months. The regimen utilizes distinct mechanisms of action to overcome drug resistance and induce apoptosis in malignant plasma cells.

Other names

CVDD regimenVDD plus cyclophosphamide